title: Treatment of mild-moderate calcified coronary lesions with sirolimus-eluting stent: real world data from a single center.
abstract: BACKGROUND
  Calcified coronary lesions have commonly been considered as a challenge for interventional cardiologists, and few previous studies of sirolimus-eluting stent (SES) for calcified lesion have been limited by small sample size. Therefore, we evaluated the effectiveness of SES implantation for the treatment of calcified lesions in a large Chinese cohort of real world practice.
  
  
  METHODS
  A total of 956 consecutive patients who successfully received SES placement were enrolled in this study, and were divided into the two groups according to whether the mild-moderate calcified lesion treated with SES exists or not: noncalcified group (n = 637) and calcified group (n = 319). Lesions treated with SES were subjected to quantitative coronary angiography immediately and 8 months after stenting.
  
  
  RESULTS
  Baseline characteristics including clinical, demographic or angiographic data were well balanced between the noncalcified and calcified groups. In the angiographic follow-up at 8 months, the in-stent restenosis and in-segment restenosis rates were similar in both the groups (in-stent restenosis: 3.8 vs. 4.0%, P>0.05; in-segment restenosis: 8.5 vs. 9.7%, P>0.05). The target lesion revascularization was not different between the two groups (5.2 vs. 6.8%; P>0.05). In addition, the in-stent late loss and overall thrombosis rate were also similar in both the groups (0.17+/-0.41 vs. 0.18+/-0.35 mm and 1.8 vs. 1.8%, P>0.05, respectively).
  
  
  CONCLUSIONS
  Although stenting of the calcified lesion was hard, successful treatment with SES for mild-moderate calcified lesions was conferred to similar favorable results compared with noncalcified lesions in patients with coronary artery disease.
authors.affiliation: Department of Cardiology, Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, PR China.
authors.forename: Jin-Qing
authors.initials: JQ
authors.lastname: Yuan
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Li
authors.forename: Xue-Wen
authors.initials: XW
authors.lastname: Qin
authors.forename: Bo
authors.initials: B
authors.lastname: Xu
authors.forename: Yue-Jin
authors.initials: YJ
authors.lastname: Yang
authors.forename: Ji-Lin
authors.initials: JL
authors.lastname: Chen
authors.forename: Shu-Bing
authors.initials: SB
authors.lastname: Qiao
authors.forename: Wei-Hua
authors.initials: WH
authors.lastname: Ma
authors.forename: Min
authors.initials: M
authors.lastname: Yao
authors.forename: Hai-Bo
authors.initials: HB
authors.lastname: Liu
authors.forename: Yong-Jian
authors.initials: YJ
authors.lastname: Wu
authors.forename: Jue
authors.initials: J
authors.lastname: Chen
authors.forename: Shi-Jie
authors.initials: SJ
authors.lastname: You
authors.forename: Jun
authors.initials: J
authors.lastname: Dai
authors.forename: Ran
authors.initials: R
authors.lastname: Xia
authors.forename: Run-Lin
authors.initials: RL
authors.lastname: Gao
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D002114:Calcinosis / Q000000981:diagnostic imaging / Q000628:therapy*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002681:China; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D020123:Sirolimus / Q000008:administration & dosage*; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D020123:Sirolimus